Wells Fargo Maintains Overweight on Regeneron Pharmaceuticals, Lowers Price Target to $1050
Portfolio Pulse from Benzinga Newsdesk
Wells Fargo analyst Mohit Bansal maintains an Overweight rating on Regeneron Pharmaceuticals but lowers the price target from $1200 to $1050.
October 22, 2024 | 9:49 pm
News sentiment analysis
Sort by:
Descending
NEUTRAL IMPACT
Wells Fargo has maintained its Overweight rating on Regeneron Pharmaceuticals but has lowered the price target from $1200 to $1050, indicating a more conservative outlook.
The maintenance of an Overweight rating suggests continued confidence in Regeneron's performance, but the lowered price target reflects a more cautious outlook, possibly due to market conditions or company-specific factors. This mixed signal may lead to neutral short-term price movement.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100